Table 3 Median OS and DFS in trials comparing gemcitabine combined with targeted therapy with gemcitabine alone.
Trial | Regimen (per arm) | No. of pts | Median OS (mons) | HR (95% CI) | p value | Median PFS/TTP (mons) | HR (95%CI) | p value |
|---|---|---|---|---|---|---|---|---|
Moore MJ 2007 | Gem/erlotinib | 285 | 6.24 | 0.82 | 0.038* | 3.75 | 0.77 | 0 .004* |
| Â | Gem | 284 | 5.91 | (0.69-0.99) | Â | 3.55 | (0.64-0.92) | Â |
Philip A 2010 | Gem/C-225 | 372 | 6.3 | 1.06 | 0 .23 | 3.4 | 1.07 | 0.18 |
| Â | Gem | 371 | 5.9 | (0.91-1.23) | Â | 3.0 | (0.93-1.24) | Â |
Van Cutsem E 2004 | Gem/tipifarnib | 341 | 6.4 | 1.03 | 0 .75 | 3.7 | 1.03 | 0 .72 |
| Â | Gem | 347 | 6.1 | (0.86-1.23) | Â | 3.6 | (0.87-1.22) | Â |
Saif W 2009 | Gem/LY293111 | 67 | 7.1 | UA | > 0.05 | 3.7 | UA | > 0.05 |
| Â | Gem | 66 | 8.3 | Â | Â | 3.4 | Â | Â |
Spano JP 2008 | Gem/axitinib | 69 | 6.9 | 0·71 | UA | 4.2 |  | UA |
| Â | Gem | 34 | 5.6 | (0.44-1.13) | Â | 3.7 | (0.43-1.45) | Â |
Bramhall SR 2002 | Gem/marimastat | 120 | 5.5 | 0.99 | 0.95 | 3.1 | 0.68 | 0.68 |
| Â | Gem | 119 | 5.5 | (0.76-1.30) | Â | 3.2 | (0.73-1.23) | Â |
Kindler HL 2010 | Gem/bevacizumab | 302 | 5.8 | 1.004 | 0.95 | 3.8 | UA | 0.075 |
| Â | Bev | 300 | 5.9 | (0.88-1.24) | Â | 2.9 | Â | Â |
Richards DA 2006 | Gem/CI-994 | 85 | 6.5 | 0.980 | 0.904 | 3.1 | 0.837 | 0.304 |
| Â | Gem | 88 | 7.1 | (0.701-1.370) | Â | 3.4 | (0.596-1.175) | Â |
Friess H 2006 | Gem/cilengitide | 46 | 6.8 | UA | > 0.05 | 3.7 | UA | > 0.05 |
| Â | Gem | 43 | 7.8 | Â | Â | 3.8 | Â | Â |